Charles River Laboratories: Retrogenix acquisition
Clinical laboratory services firm Charles River Laboratories has acquired Retrogenix, an early-stage CRO offering bioanalytical services, including cell microarray technology.
James Foster (chair, president and CEO of Charles River Laboratories) said, “The acquisition of Retrogenix strategically expands Charles River’s existing discovery capabilities by adding a proprietary cell microarray technology to accelerate target identification and provide preclinical safety assurance for novel therapies.”
